Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...
BridgeBio Pharma Announces CHMP's Positive Recommendation Of Acoramidis - Quick Facts
BridgeBio Pharma (BBIO) announced the Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion ...
Business Insider20h
BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment
BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization in the European Union for acoramidis for ...
FiercePharma11h
EMA backs Merck’s Welireg, Bayer’s ATTR med and Gilead’s liver drug from $4.3B deal
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
Bayer Gets EU Backing for Heart Drug, Easing Patent Concerns
Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...
The Pharma Letter9h
EMA/CHMP backs bumper crop of new medicines for approval
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at ...
pharmaphorum2d
Bayer pays $310m for Euro rights to ATTR therapy acoramidis
Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the therapy for transthyretin ...
pharmaphorum4d
Alnylam hails vutrisiran data, but investors seem sceptical
One reason for the fall could be the competitive threat posed by BridgeBio’s acoramidis, which demonstrated a 42% reduction in all-cause mortality and recurrent cardiovascular events in its ...